Cancer Genetic Testing in Ethnic Populations
This study is looking at how cancer genetic testing can be used in different ethnic groups. If you have been diagnosed with a solid tumor cancer (like breast, digestive, or brain cancer) and are receiving care at Mayo Clinic in Arizona or Florida, you might be able to join. The study involves collecting a blood sample for genetic testing. Researchers want to find out how common certain genetic changes are in cancer patients from various ethnic backgrounds. This information could help doctors better understand cancer risks and personalize screening for these populations.
- Study design
- This is an interventional study planning to enroll 1800 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would provide a blood or saliva sample for genetic testing. The study completion is expected in 2 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes will be measured at the study's completion, which is 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cancer Genetic Testing in Ethnic Populations
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Jewel Samadder, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Prevalence of pathogenic germline mutations in enrolled patients within each cancer siteStudy completion (2 years)
Will identify the prevalence of pathogenic germline mutations in enrolled patients within each cancer site, age (\< 60 years old versus (vs.) \>= 60 years old), and stage (early vs. advanced) via descriptive statistics.
- Prevalence of positive pathogenic germline mutationsStudy completion (2 years)
Will determine whether the prevalence of positive pathogenic germline mutations differs between cancer sites, age of diagnosis, and stage of diagnosis using logistic regression analysis across all cancer site groups and pairwise post-hoc analyses using Tukey's correction for multiple comparisons across pairs of cancer sites and chi-square tests of differences between age and stage groups.
- Rate of mutation detection via genetic testing to clinical practice guidelines of traditional family history criteriaStudy completion (2 years)
Will compare the rate of mutation detection via genetic testing to clinical practice guidelines of traditional family history criteria within cancer site, age, and stage using logistic regression and pairwise post-hoc analyses as needed.
- Impact of germline genetic testing on both therapeutic management and targeted cancer preventionStudy completion (2 years)
Will assess the impact of germline genetic testing on both therapeutic management and targeted cancer prevention in family members using logistic regression and pairwise post-hoc analyses as needed.